Advertisement
News
Advertisement

RXi Pharmaceuticals lands SBIR grants for RNAi therapeutics(2)

Tue, 04/26/2011 - 8:37am
Mass High Tech: The Journal of New England Technology

Worcester RNAi therapeutics firm RXi Pharmaceuticals Corp. has won a total of almost $580,000 from two Small Business Innovation Research grants awarded through the National Institutes of Health.

The National Institute of Neurological Disorders and Stroke offered the first grant, for $304,559, to address Phase 1 of a project aimed at developing RNAi treatment for amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders. A news release today noted that RXi can apply for more funding to move the project into Phase 2.

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading